How do life sciences companies build an IT landscape that is GxP-compliant, validated and at the same time fast enough for the business?
We connect Business, Data and IT for validated GxP-relevant systems in Life Sciences: technology assessment, validation per GAMP 5, data integrity and audit trails. Where validation readiness, data integrity and supplier qualification are checked only after selection, technical debt makes every later inspection expensive.
Overview
What requirements does the regulatory framework place on IT systems in life sciences?
GxP IT across pharma, biotech, MedTech & IVD · GAMP 5, 21 CFR Part 11, EU GMP Guide Annex 11, AI Act (EU) 2024/1689
Last updated: June 13, 2026
As soon as an IT system creates, processes or stores GxP-relevant data, it becomes a regulated object in its own right. Selection, implementation and operation must meet the requirements for validation and data integrity, otherwise the system becomes a weak point in the audit instead of a lever for efficiency.
- Validation readiness as a selection criterion: a GxP-relevant system must be capable of being validated on a risk-based approach under GAMP 5. Audit trail capability, access controls and available supplier validation documentation are decided before the purchase, not at go-live.
- Data integrity to ALCOA+: Electronic records must be attributable, legible, contemporaneous, original and accurate, complemented by complete, consistent, enduring and available. 21 CFR Part 11 and the EU GMP Guide Annex 11 require tamper-evident audit trails and unambiguous user authentication.
- Supplier and cloud responsibility: For SaaS and cloud hosting of GxP-relevant data, regulatory responsibility remains with the regulated company. The provider must be assessed against 21 CFR Part 11, Annex 11 and EU GMP Guide Chapter 4.
- AI in regulated operation: Data-driven and AI-supported applications are additionally subject to the AI Act (EU) 2024/1689, whose obligations are calibrated to the risk of the application. Data with a personal reference falls in parallel under the GDPR (EU) 2016/679.
Services
How we support you
Technology strategy & system selection
As-is analysis of the existing IT landscape, requirements catalog and structured selection process with a regulatory pre-assessment of validation readiness. Deliverable: an assessed technology roadmap prioritized by business value and GxP risk.
GxP IT supplier & cloud assessment
Vendor assessment of software suppliers and cloud providers against 21 CFR Part 11, Annex 11 and EU GMP Guide Chapter 4. Deliverable: a supplier audit report with an assessment of the outsourced electronic records.
Implementation & integration support
Project management or support for IT implementations, including requirements engineering, interface design and coordination with the validation activities. Deliverable: an implementation plan with an integrated validation and data migration concept.
How we work together
What it comes down to
In regulated environments, a broader feature set does not get a system into operation any faster; the evidence does.
Three pieces of it must line up before a system goes into production: validation readiness under GAMP 5, data integrity to ALCOA+ with a tamper-evident audit trail against 21 CFR Part 11 and the EU GMP Guide Annex 11, and supplier responsibility for outsourced records.
Companies that examine these strands only after the selection decision lose the weakest one as a bottleneck, usually the validation readiness of a system that has already been purchased. That is precisely why the regulatory pre-assessment belongs at the start of the selection process and not at the end of the implementation.
The second lever is the data architecture across system boundaries. Every uncontrolled transfer between silos that have grown over time is a potential data integrity breach, which Annex 11 requires to be a controlled, traceable process.
Once data-driven or AI-supported applications are added, the AI Act (EU) 2024/1689 adds a risk-based layer of obligations, and where there is a personal reference the GDPR (EU) 2016/679 applies in parallel.
We therefore start early: first assess the GxP relevance and the risk of each application, then anchor validation, audit trail review and data protection while that is still possible without production pressure.
Our approach
Our approach
Step
Result
As-is analysis & requirements
Documented IT landscape, GxP relevance assessed per system, prioritized requirements catalog.
System selection & pre-assessment
Assessed options with supplier qualification and a pre-assessment of validation readiness under GAMP 5.
Implementation & integration
Configured system with defined interfaces, access concept and data migration plan.
Validation & data integrity
Validation documentation under GAMP 5, activated audit trails and ALCOA+ compliant records.
Go-live & audit trail review
Productive operation with a documented audit trail review routine and supplier governance.
Common pitfalls
Where projects commonly fail
Validation readiness is examined only after the system has been selected.
If a system is purchased without sufficient audit trail capability or without available supplier validation documentation, it can be validated under GAMP 5 only with considerable additional effort, or it lacks GxP suitability altogether.
The audit trail exists but is switched off or is never reviewed.
An audit trail that is available at the system level but deactivated or never reviewed satisfies neither 21 CFR Part 11 nor Annex 11. Without a documented review routine, the gap remains undetected until inspection.
GxP data moves to the cloud without a supplier assessment.
Data is hosted on SaaS or cloud infrastructure without the provider having been assessed against 21 CFR Part 11, Annex 11 and EU GMP Guide Chapter 4. Responsibility for the outsourced records remains with the regulated company.
AI applications go into operation without regulatory classification.
A data-driven application is put into productive use before its obligations under the AI Act (EU) 2024/1689 have been clarified and before any personal reference has been checked against the GDPR. Traceability and validation scope are difficult to establish after the fact.
Systems that have grown over time remain unintegrated.
Without an overarching architecture, silos arise with duplicate data entry and media breaks. Every uncontrolled data transfer between systems is a potential data integrity breach, which Annex 11 requires to be a controlled, traceable process.
Supply Chain & Technical Operations
Do any of these pitfalls apply to you?
In a first call we assess your situation and say what needs clarifying first in your case. Without obligation, reply usually within one working day.
FAQ
Frequently asked questions
Sources
- 21 CFR Part 11 (FDA) - Electronic Records; Electronic Signatures, primary text
- EU GMP Guide Annex 11 - Computerised Systems
- EU GMP Guide Chapter 4 - Documentation
- GAMP 5 (ISPE) - A Risk-Based Approach to Compliant GxP Computerised Systems
- Regulation (EU) 2024/1689 (AI Act) - primary text
- Regulation (EU) 2016/679 (GDPR) - primary text
- Technology Excellence source material (Entourage writer output, business-data-it)
Life Science Journal
Regulatory updates, straight to your inbox.
New requirements, authority decisions and practice notes. Once a month, unsubscribe any time.
Case Studies
What this looks like in practice
Latest insights
All insights →Regulations & standards considered
- 21 CFR Part 11 (FDA, Electronic Records; Electronic Signatures)
- EU GMP Guide Annex 11 (Computerised Systems)
- EU GMP Guide Chapter 4 (Documentation)
- GAMP 5 (ISPE, A Risk-Based Approach to Compliant GxP Computerised Systems)
- AI Act (EU) 2024/1689
- General Data Protection Regulation (EU) 2016/679 (GDPR)
Related topics
Computer System Validation (CSV) →
Risk-based CSV under GAMP 5 for GxP-relevant systems
21 CFR Part 11 & Data Integrity →
Audit trail, e-signature and ALCOA+ in detail
EU AI Act →
Obligations of AI-supported applications under the AI Act (EU) 2024/1689
Digital Governance →
Governance framework for digital systems and data flows
Have a concrete project?
Briefly outline your situation. We'll respond with an initial assessment, usually within one business day.
Prefer direct? +39 02 8904 1000
info@theentourage.it
- Reply usually within one working day
- 4 offices: DE · CH · IT · US
- 100% life sciences